Dysmenorrhea Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

05:10 EDT 31 Jul 2017 | BioPortfolio Reports

DelveInsight's, Dysmenorrhea Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Dysmenorrhea. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Dysmenorrhea. This report provides information on the therapeutic development for Dysmenorrhea, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Aclaris Therapeutics Inc.
Allergan Plc
Almirall S.A.
Androscience Corporation
Anticancer Inc.
Applied Biology
Berg LLC
Biologicsmd Inc.
DongA St Co. Ltd.
Eli Lilly And Company
Follica Bio
Follicum AB
Glaxosmithkline Plc.
Histogen Inc
Diffusion Pharmaceuticals Inc
Hyundai Pharmaceutical Co. Ltd.
Incyte Corporation
Kerastem Technologies Llc
Kuhnil Pharmaceutical Co. Ltd.
Lee's Pharmaceutical Holdings Limited
Leo Pharma
Merck Co
Novalead Pharma Pvt. Ltd.
Procertus Biopharm Inc.
Quark Pharmaceuticals Inc.
Regenerx Biopharmaceuticals Inc.
Replicel Life Sciences Inc.
Rnl Bio Co. Ltd
Rxi Pharmaceuticals Corporation
Samumed LLC
Sucampo Pharmaceuticals Inc.
Switch Biotech Llc
Tetralogic Pharmaceuticals
Tigo Gmbh
Vida Therapeutics Inc.
Dysmenorrhea Pipeline Drugs
Dysmenorrhea Pipeline Assessment
Dysmenorrhea Pipeline Analysis
Dysmenorrhea Drugs under Development
Dysmenorrhea Discovery drugs
Dysmenorrhea Preclinical drugs
Dysmenorrhea Phase I drugs
Dysmenorrhea Phase II drugs
Dysmenorrhea Phase III Pipeline Drugs Assessment
Dysmenorrhea Preregistration drugs
Dysmenorrhea Molecules in pipeline

Original Article: Dysmenorrhea Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000


More From BioPortfolio on "Dysmenorrhea Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...